Tango Therapeutics (TNGX) is up 34.1% today. Here is some analysis on what might have caused this price movement.
Analysis: The move appears tied to newly disclosed early clinical results for the company’s lead PRMT5 inhibitor, vopimetostat, in combination with Revolution Medicines’ RAS(ON) inhibitor daraxonrasib in MTAP-deleted, RAS-mutant pancreatic cancer. Investors likely reacted to the headline objective response rate and the company’s stated intent to advance the regimen toward later-stage development.
Details:
Sources:
SEC (EDGAR), GlobeNewswire, STAT News
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$TNGX Insider Trading Activity
$TNGX insiders have traded $TNGX stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $TNGX stock by insiders over the last 6 months:
- ADAM CRYSTAL (President, R&D) has made 0 purchases and 11 sales selling 224,508 shares for an estimated $4,190,240.
- BARBARA WEBER (Director, Executive Chair) has made 0 purchases and 2 sales selling 30,519 shares for an estimated $374,293.
- DANIELLA BECKMAN (Chief Financial Officer) has made 0 purchases and 2 sales selling 10,317 shares for an estimated $126,530.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TNGX Hedge Fund Activity
We have seen 117 institutional investors add shares of $TNGX stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 11,809,392 shares (+791.9%) to their portfolio in Q1 2026, for an estimated $247,052,480
- ECOR1 CAPITAL, LLC removed 10,630,736 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $94,188,320
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 10,298,485 shares (+410.1%) to their portfolio in Q1 2026, for an estimated $215,444,306
- FMR LLC added 7,038,371 shares (+245.4%) to their portfolio in Q1 2026, for an estimated $147,242,721
- GILEAD SCIENCES, INC. removed 4,854,443 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $43,010,364
- PARADIGM BIOCAPITAL ADVISORS LP added 4,009,679 shares (+inf%) to their portfolio in Q1 2026, for an estimated $83,882,484
- FARALLON CAPITAL MANAGEMENT LLC removed 3,964,000 shares (-30.3%) from their portfolio in Q1 2026, for an estimated $82,926,880
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TNGX Price Targets
Multiple analysts have issued price targets for $TNGX recently. We have seen 9 analysts offer price targets for $TNGX in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Kelsey Goodwin from Piper Sandler set a target price of $24.0 on 05/15/2026
- Joseph Catanzaro from Mizuho set a target price of $30.0 on 05/15/2026
- Robert Driscoll from Wedbush set a target price of $33.0 on 05/14/2026
- Maury Raycroft from Jefferies set a target price of $27.0 on 05/14/2026
- Andrew Berens from Leerink Partners set a target price of $55.0 on 05/14/2026
- Laura Prendergast from Stifel set a target price of $40.0 on 04/27/2026
- John Newman from Canaccord Genuity set a target price of $30.0 on 04/02/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
